Novartis' Bexsero becomes first approved meningitis B vaccine in Europe
This article was originally published in Scrip
Executive Summary
Novartis has received European Commission approval for use of the meningitis B vaccine in individuals aged two months and older and said it was committed to making Bexsero available as soon as possible.